Claudia A Chiriboga1, Louise Kuhn2, Gail A Wasserman3. 1. Division of Pediatric Neurology, Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, USA ; Sergievsky Center, Columbia University, New York, NY, USA ; Harlem Hospital Center, New York, NY, USA. 2. Sergievsky Center, Columbia University, New York, NY, USA. 3. Division of Child and Adolescent Psychiatry, Department of Psychiatry, Columbia University, New York, NY, USA ; New York Psychiatric Institute, New York, NY, USA.
Abstract
INTRODUCTION: In experimental models, prenatal cocaine exposure has been found to perturb GABA and dopamine development. Clinically, abnormalities in tone, posture and state regulation are noted in early infancy but the evolution of these findings over time is not well described. The current study assesses the longitudinal effects of prenatal cocaine exposure in dose-dependent fashion on developmental & behavioral and neurological trajectories over the first 2 years of life. METHODS: Three hundred and eighty infants, 113 cocaine-exposed, were enrolled at birth from an urban hospital from 2000 to 2004. Exposure was determined by maternal interview, segmental hair analyses (RIAH™) in all, and meconium and urine in a subset. Developmental, behavioral and neurological assessments were carried out blind to drug exposure at 6, 12 and 24 months of age in the 306 children who returned in follow-up. Mixed-effects linear modeling (developmental growth curve) assessed change in outcome over time. RESULTS: The mental developmental growth curve showed a negative slope (2.2 points) in adjusted analyses among cocaine-exposed children over the first 2 years of life. (p=.04), while the slope of the motor development growth curve did not. Adjusting for microcephaly at 6 months diminished the strength of the association between cocaine exposure and mental developmental growth curve (effect modification). Cocaine exposure was marginally associated with behavioral outcomes in adjusted analyses. Total Behavior scores and Orientation/Engagement scores improved with age. At 1 year of age, prenatal cocaine exposure was significantly associated with lower motor development scores. High rates of hypertonia (global and diparesis) identified at the 6-month visit dropped dramatically in the first 2 years of life: cocaine-exposed children showed a more rapid rate of resolution of hypertonia than unexposed children, with hypertonia improving 2.2 times faster among those with heavy cocaine exposure. CONCLUSION: We found differences in mental performance over the first 2 years of life associated with prenatal cocaine exposure that was mediated by microcephaly implying that cocaine exerts a sustained teratogenic effect on brain development. Early neurological (hypertonia) and behavioral findings associated with prenatal cocaine exposure improved over time. Hypertonia did not predict long-term development impairments. Conceivably, the transient nature of neurobehavioral manifestations reflects postnatally a tendency towards homeostasis of cocaine-related embryopathic perturbations of GABA and dopaminergic systems.
INTRODUCTION: In experimental models, prenatal cocaine exposure has been found to perturb GABA and dopamine development. Clinically, abnormalities in tone, posture and state regulation are noted in early infancy but the evolution of these findings over time is not well described. The current study assesses the longitudinal effects of prenatal cocaine exposure in dose-dependent fashion on developmental & behavioral and neurological trajectories over the first 2 years of life. METHODS: Three hundred and eighty infants, 113 cocaine-exposed, were enrolled at birth from an urban hospital from 2000 to 2004. Exposure was determined by maternal interview, segmental hair analyses (RIAH™) in all, and meconium and urine in a subset. Developmental, behavioral and neurological assessments were carried out blind to drug exposure at 6, 12 and 24 months of age in the 306 children who returned in follow-up. Mixed-effects linear modeling (developmental growth curve) assessed change in outcome over time. RESULTS: The mental developmental growth curve showed a negative slope (2.2 points) in adjusted analyses among cocaine-exposed children over the first 2 years of life. (p=.04), while the slope of the motor development growth curve did not. Adjusting for microcephaly at 6 months diminished the strength of the association between cocaine exposure and mental developmental growth curve (effect modification). Cocaine exposure was marginally associated with behavioral outcomes in adjusted analyses. Total Behavior scores and Orientation/Engagement scores improved with age. At 1 year of age, prenatal cocaine exposure was significantly associated with lower motor development scores. High rates of hypertonia (global and diparesis) identified at the 6-month visit dropped dramatically in the first 2 years of life: cocaine-exposed children showed a more rapid rate of resolution of hypertonia than unexposed children, with hypertonia improving 2.2 times faster among those with heavy cocaine exposure. CONCLUSION: We found differences in mental performance over the first 2 years of life associated with prenatal cocaine exposure that was mediated by microcephaly implying that cocaine exerts a sustained teratogenic effect on brain development. Early neurological (hypertonia) and behavioral findings associated with prenatal cocaine exposure improved over time. Hypertonia did not predict long-term development impairments. Conceivably, the transient nature of neurobehavioral manifestations reflects postnatally a tendency towards homeostasis of cocaine-related embryopathic perturbations of GABA and dopaminergic systems.
Authors: Zhihao Li; Priya Santhanam; Claire D Coles; Mary Ellen Lynch; Stephan Hamann; Scott Peltier; Xiaoping Hu Journal: Hum Brain Mapp Date: 2011-05 Impact factor: 5.038
Authors: Emmalee S Bandstra; Connie E Morrow; Veronica H Accornero; Elana Mansoor; Lihua Xue; James C Anthony Journal: Neurotoxicol Teratol Date: 2011 Jan-Feb Impact factor: 3.763
Authors: G Wasserman; J H Graziano; P Factor-Litvak; D Popovac; N Morina; A Musabegovic; N Vrenezi; S Capuni-Paracka; V Lekic; E Preteni-Redjepi Journal: J Pediatr Date: 1992-11 Impact factor: 4.406
Authors: G A Wasserman; J K Kline; D A Bateman; C Chiriboga; L H Lumey; H Friedlander; L Melton; M C Heagarty Journal: Drug Alcohol Depend Date: 1998-05-01 Impact factor: 4.492
Authors: Chun-Ting Lee; Jia Chen; Teruo Hayashi; Shang-Yi Tsai; Joseph F Sanchez; Stacie L Errico; Rose Amable; Tsung-Ping Su; Ross H Lowe; Marilyn A Huestis; James Shen; Kevin G Becker; Herbert M Geller; William J Freed Journal: PLoS Med Date: 2008-06-10 Impact factor: 11.069
Authors: Tatiana A Shnitko; Kyla D Mace; Kaitlin M Sullivan; W Kyle Martin; Elizabeth H Andersen; Sarah K Williams Avram; Josephine M Johns; Donita L Robinson Journal: Behav Pharmacol Date: 2017-12 Impact factor: 2.293